Status:
COMPLETED
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lymphoma
Eligibility:
All Genders
18-120 years
Phase:
PHASE2
Brief Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them o...
Detailed Description
OBJECTIVES: Primary * Investigate plasma DNA biomarkers, including plasma clonal immunoglobulin DNA, tumor suppressor gene methylation, and Epstein-Barr virus DNA, in patients receiving rituximab an...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed classical Hodgkin's lymphoma
- No lymphocyte-predominant histology
- Stage II, III, or IV disease
- Newly diagnosed disease
- PATIENT CHARACTERISTICS:
- Performance status 0-2
- Creatinine \< 2.0 mg/dL
- Bilirubin \< 5 mg/dL
- Not pregnant or nursing
- No HIV positivity
- Hepatitis B surface antigen negative
- No active concurrent malignancy except for superficial nonmelanoma skin cancer or cervical carcinoma in situ
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or radiotherapy for Hodgkin's lymphoma
- Steroids allowed if medically required before chemotherapy initiation
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2014
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00369681
Start Date
May 1 2006
End Date
October 1 2014
Last Update
August 27 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000
2
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States, 52242-1009
3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
4
Mayo Clinic Cancer Center
Rochester, Minnesota, United States, 55905